Literature DB >> 20201891

Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy.

Izhak Kehat1, Jeffery D Molkentin.   

Abstract

Cardiac hypertrophy results from increased mechanical load on the heart and through the action of neurohumoral mediators. ERK1/2 are known to be activated in response to almost every stress- and agonist-induced hypertrophic stimulus examined to date, suggesting the straightforward hypothesis that these kinases are required for promoting the cardiac growth response. However, recent data from genetically modified mouse models suggest a more complicated picture. For example, inducible expression of dual-specificity phosphatase 6, an ERK1/2-inactivating phosphatase, eliminated ERK1/2 phosphorylation in transgenic mice, but it did not diminish the hypertrophic response to pressure overload. Similarly, Erk1-/- and Erk2+/- mice showed no reduction in stimulus-induced cardiac growth in vivo. However, blockade or deletion of cardiac ERK1/2 did predispose the heart to decompensation and failure after long-term pressure overload. Thus, ERK1/2 signaling is not to be absolutely necessary for mediating cardiac hypertrophy, although it does appear to provide critical protective effects/signals during stress-stimulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20201891      PMCID: PMC5941943          DOI: 10.1111/j.1749-6632.2009.05088.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  24 in total

Review 1.  Organization and regulation of mitogen-activated protein kinase signaling pathways.

Authors:  T P Garrington; G L Johnson
Journal:  Curr Opin Cell Biol       Date:  1999-04       Impact factor: 8.382

Review 2.  The MEK/ERK cascade: from signaling specificity to diverse functions.

Authors:  Yoav D Shaul; Rony Seger
Journal:  Biochim Biophys Acta       Date:  2006-10-19

3.  The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice.

Authors:  O F Bueno; L J De Windt; K M Tymitz; S A Witt; T R Kimball; R Klevitsky; T E Hewett; S P Jones; D J Lefer; C F Peng; R N Kitsis; J D Molkentin
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

4.  Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy.

Authors:  G J Babu; M J Lalli; M A Sussman; J Sadoshima; M Periasamy
Journal:  J Mol Cell Cardiol       Date:  2000-08       Impact factor: 5.000

5.  Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice.

Authors:  J J Hunter; N Tanaka; H A Rockman; J Ross; K R Chien
Journal:  J Biol Chem       Date:  1995-09-29       Impact factor: 5.157

6.  Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases.

Authors:  C F Zheng; K L Guan
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

7.  Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo.

Authors:  Nicole H Purcell; Benjamin J Wilkins; Allen York; Marc K Saba-El-Leil; Sylvain Meloche; Jeffrey Robbins; Jeffery D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-20       Impact factor: 11.205

Review 8.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

9.  The epidemiology of heart failure: the Framingham Study.

Authors:  K K Ho; J L Pinsky; W B Kannel; D Levy
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

10.  DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility.

Authors:  Marjorie Maillet; Nicole H Purcell; Michelle A Sargent; Allen J York; Orlando F Bueno; Jeffery D Molkentin
Journal:  J Biol Chem       Date:  2008-08-27       Impact factor: 5.157

View more
  54 in total

Review 1.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

Review 2.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

3.  IQGAP1 regulates ERK1/2 and AKT signalling in the heart and sustains functional remodelling upon pressure overload.

Authors:  Mauro Sbroggiò; Daniela Carnevale; Alessandro Bertero; Giuseppe Cifelli; Emanuele De Blasio; Giada Mascio; Emilio Hirsch; Wadie F Bahou; Emilia Turco; Lorenzo Silengo; Mara Brancaccio; Giuseppe Lembo; Guido Tarone
Journal:  Cardiovasc Res       Date:  2011-04-14       Impact factor: 10.787

4.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

5.  ERK1/2 activation in heart is controlled by melusin, focal adhesion kinase and the scaffold protein IQGAP1.

Authors:  Mauro Sbroggiò; Alessandro Bertero; Silvia Velasco; Federica Fusella; Emanuele De Blasio; Wadie F Bahou; Lorenzo Silengo; Emilia Turco; Mara Brancaccio; Guido Tarone
Journal:  J Cell Sci       Date:  2011-10-15       Impact factor: 5.285

Review 6.  Molecular basis of physiological heart growth: fundamental concepts and new players.

Authors:  Marjorie Maillet; Jop H van Berlo; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2013-01       Impact factor: 94.444

7.  Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts.

Authors:  Nina Kaludercic; Andrea Carpi; Takahiro Nagayama; Vidhya Sivakumaran; Guangshuo Zhu; Edwin W Lai; Djahida Bedja; Agnese De Mario; Kevin Chen; Kathleen L Gabrielson; Merry L Lindsey; Karel Pacak; Eiki Takimoto; Jean C Shih; David A Kass; Fabio Di Lisa; Nazareno Paolocci
Journal:  Antioxid Redox Signal       Date:  2013-05-22       Impact factor: 8.401

Review 8.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

9.  Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

Authors:  Catharina Ruppert; Katharina Deiss; Sebastian Herrmann; Marie Vidal; Mehmet Oezkur; Armin Gorski; Frank Weidemann; Martin J Lohse; Kristina Lorenz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

10.  Protective role of AT(2) and B(1) receptors in kinin B(2)-receptor-knockout mice with myocardial infarction.

Authors:  Jiang Xu; Oscar A Carretero; Liping Zhu; Edward G Shesely; Nour-Eddine Rhaleb; Xiangguo Dai; Luchen Wang; James J Yang; Xiao-Ping Yang
Journal:  Clin Sci (Lond)       Date:  2013-01       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.